201 related articles for article (PubMed ID: 33714919)
1. The current landscape of the FDA approved companion diagnostics.
Jørgensen JT
Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
[TBL] [Abstract][Full Text] [Related]
2. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
3. Oncology drug-companion diagnostic combinations.
Jørgensen JT
Cancer Treat Res Commun; 2021; 29():100492. PubMed ID: 34844911
[TBL] [Abstract][Full Text] [Related]
4. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs.
Jørgensen JT
JCO Precis Oncol; 2022 Jun; 6():e2200100. PubMed ID: 35709402
[TBL] [Abstract][Full Text] [Related]
5. Twenty-five years with companion diagnostics.
Jørgensen JT
Chin Clin Oncol; 2023 Dec; 12(6):65. PubMed ID: 37953243
[TBL] [Abstract][Full Text] [Related]
6. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
7. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
Jørgensen JT
Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518
[TBL] [Abstract][Full Text] [Related]
8. The Regulation of Companion Diagnostics: A Global Perspective.
Ansari M
Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
[TBL] [Abstract][Full Text] [Related]
9. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
Olsen D; Jørgensen JT
Front Oncol; 2014; 4():105. PubMed ID: 24904822
[TBL] [Abstract][Full Text] [Related]
10. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
11. Protein array-based companion diagnostics in precision medicine.
Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
[TBL] [Abstract][Full Text] [Related]
12. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Hersom M; Jørgensen JT
Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
[TBL] [Abstract][Full Text] [Related]
13. Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS.
Kang SL; Woo JH; Kim NH; Kwon JY; Kim SM
Mol Ther Methods Clin Dev; 2023 Sep; 30():447-458. PubMed ID: 37663648
[TBL] [Abstract][Full Text] [Related]
14. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
Tanaka A; Suzuki H; Toyoshima S; Nagai N
Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
[TBL] [Abstract][Full Text] [Related]
15. Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics.
Meehan RT; Amigues IA; Knight V
Diagnostics (Basel); 2021 Jul; 11(8):. PubMed ID: 34441297
[TBL] [Abstract][Full Text] [Related]
16. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics.
Pant S; Weiner R; Marton MJ
Front Oncol; 2014; 4():78. PubMed ID: 24860780
[TBL] [Abstract][Full Text] [Related]
17. [Current Status and Regulatory Issues of Companion Diagnostics in Japan].
Tsukumo Y; Inoue T
Gan To Kagaku Ryoho; 2024 Apr; 51(4):368-377. PubMed ID: 38644299
[TBL] [Abstract][Full Text] [Related]
18. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
19. Companion Diagnostics and Molecular Imaging.
Puranik AD; Kulkarni HR; Baum RP
Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701
[TBL] [Abstract][Full Text] [Related]
20. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]